

# Mei-Jyh Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8752742/publications.pdf>

Version: 2024-02-01

35  
papers

1,887  
citations

279701

23  
h-index

360920

35  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Declining trends of prevalence of <i>Helicobacter pylori</i> infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysis. <i>Helicobacter</i> , 2022, 27, .	1.6	8
2	Alteration of taste or smell as a predictor of COVID-19. <i>Gut</i> , 2021, 70, 806-807.	6.1	13
3	The efficacy of <i>Lactobacillus acidophilus</i> and <i>rhamnosus</i> in the reduction of bacterial load of <i>Helicobacter pylori</i> and modification of gut microbiota—a double-blind, placebo-controlled, randomized trial. <i>Helicobacter</i> , 2021, 26, e12857.	1.6	18
4	Application of <i>Helicobacter pylori</i> stool antigen test to survey the updated prevalence of <i>Helicobacter pylori</i> infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 233-240.	1.4	9
5	Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensus. <i>Gut</i> , 2020, 69, 2093-2112.	6.1	239
6	Comparison of the effect of clarithromycin triple therapy with or without <i>N</i> -acetylcysteine in the eradication of <i>Helicobacter pylori</i> : a randomized controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092730.	1.4	5
7	Accuracy of rapid <i>Helicobacter pylori</i> antigen tests for the surveillance of the updated prevalence of <i>H. pylori</i> in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1626-1633.	0.8	13
8	Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after <i>Helicobacter pylori</i> eradication: a multicentre, open-label, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1109-1120.	4.6	127
9	Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2018, 155, 1109-1119.	0.6	66
10	Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2018, 113, 1444-1457.	0.2	28
11	14-day sequential therapy versus 10-day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of <i>Helicobacter pylori</i> : a multicentre, non-inferiority, randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2510-2518.	1.3	20
12	Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for <i>Helicobacter pylori</i> eradication: analysis of five randomized trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3481-3489.	1.3	23
13	Distinct Clinicopathological Features and Prognosis of <i>Helicobacter pylori</i> Negative Gastric Cancer. <i>PLoS ONE</i> , 2017, 12, e0170942.	1.1	33
14	Authors' reply to: Statins and the risk of pancreatic cancer in type 2 diabetic patients: Immortal time bias in survival analysis?. <i>International Journal of Cancer</i> , 2016, 139, 1182-1183.	2.3	1
15	Statins and the risk of pancreatic cancer in Type 2 diabetic patients—A population-based cohort study. <i>International Journal of Cancer</i> , 2016, 138, 594-603.	2.3	45
16	Sequential therapy for 10...days versus triple therapy for 14...days in the eradication of <i>Helicobacter pylori</i> in the community and hospital populations: a randomised trial. <i>Gut</i> , 2016, 65, 1784-1792.	6.1	71
17	Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet, The</i> , 2016, 388, 2355-2365.	6.3	128
18	Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of <i>Helicobacter pylori</i> : A Randomized Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, 381-387.	0.2	43

#	ARTICLE	IF	CITATIONS
19	Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 63, 1111-1117.	1.8	82
20	The Primary Resistance of <i>Helicobacter pylori</i> in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study. <i>PLoS ONE</i> , 2015, 10, e0124199.	1.1	74
21	Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria. <i>Gut</i> , 2015, 64, 1517-1528.	6.1	64
22	Target-controlled infusion of propofol versus intermittent bolus of a sedative cocktail regimen in deep sedation for gastrointestinal endoscopy: Comparison of cardiovascular and respiratory parameters. <i>Journal of Digestive Diseases</i> , 2014, 15, 18-26.	0.7	24
23	Performance of a one-step fecal sample-based test for diagnosis of <i>Helicobacter pylori</i> infection in primary care and mass screening settings. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 899-907.	0.8	29
24	Sequential versus triple therapy for the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet</i> , The, 2013, 381, 205-213.	6.3	233
25	Accuracy of faecal occult blood test and <i>Helicobacter pylori</i> stool antigen test for detection of upper gastrointestinal lesions. <i>BMJ Open</i> , 2013, 3, e003989.	0.8	24
26	Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory <i>Helicobacter pylori</i> infection: a multicentre clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 450-456.	1.3	82
27	Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1387-1395.	1.0	41
28	Genotypic Resistance in <i>Helicobacter pylori</i> Strains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1123-1129.	1.4	61
29	Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for <i>Helicobacter pylori</i> infection: a multicentre clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1847-1852.	1.3	46
30	Plasma Insulin-Like Growth Factor-Binding Protein-2 Levels as Diagnostic and Prognostic Biomarker of Colorectal Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1717-1725.	1.8	71
31	Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for <i>Helicobacter pylori</i> infection: a randomised comparative trial with crossover design. <i>Gut</i> , 2010, 59, 572-578.	6.1	100
32	Male Gender and Renal Dysfunction are Predictors of Adverse Outcome in Nonpostoperative Ischemic Colitis Patients. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e96-e100.	1.1	31
33	Gastroesophageal Reflux Disease and Sleep Quality in a Chinese Population. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 53-60.	0.8	26
34	Ultrasonographic Patterns of Non-neoplastic Small Bowel Diseases. <i>Journal of Medical Ultrasound</i> , 2006, 14, 79-85.	0.2	1
35	Optimization of Timing of Endoscopic Variceal Ligation of Esophageal Varices. <i>American Journal of Gastroenterology</i> , 2006, 101, 908-908.	0.2	8